Daniel Orrego

It would be every day? No, it would be at interval. Yeah, so not with the six diazo protocol, you're doing that on every fourth day. And then there's an interval period between dosing. This goes back to the dosing timing and scheduling components. But on the days that you are dosing it, you want to make sure everything is in play, right? You've got your glucose where you want it.

You've got your other substrates on board. You dose the DON just prior to entering the hyperbaric chamber. Okay, what's happening here? You're metabolically isolating cancer in a way where it's two primary fuel substrates, the glucose and the glutamine, are in short supply.

You've got your other substrates on board. You dose the DON just prior to entering the hyperbaric chamber. Okay, what's happening here? You're metabolically isolating cancer in a way where it's two primary fuel substrates, the glucose and the glutamine, are in short supply.

You've got your other substrates on board. You dose the DON just prior to entering the hyperbaric chamber. Okay, what's happening here? You're metabolically isolating cancer in a way where it's two primary fuel substrates, the glucose and the glutamine, are in short supply.

You're using mebendazole, whose mechanism of action is to inhibit the formation of microtubules, very important for cellular proliferation. and division within cancer cells. And then you're further impugning tumor viability by massively upregulating reactive oxygen species with the use of hyperbaric oxygen therapy. So this is where you are quite quantifiably producing tumor cell death.

You're using mebendazole, whose mechanism of action is to inhibit the formation of microtubules, very important for cellular proliferation. and division within cancer cells. And then you're further impugning tumor viability by massively upregulating reactive oxygen species with the use of hyperbaric oxygen therapy. So this is where you are quite quantifiably producing tumor cell death.

You're using mebendazole, whose mechanism of action is to inhibit the formation of microtubules, very important for cellular proliferation. and division within cancer cells. And then you're further impugning tumor viability by massively upregulating reactive oxygen species with the use of hyperbaric oxygen therapy. So this is where you are quite quantifiably producing tumor cell death.

And the great news is, is one can refer to the magnificent work of Dr. D'Agostino, which demonstrates these mechanisms of action. These are known quantities. Yeah.

And the great news is, is one can refer to the magnificent work of Dr. D'Agostino, which demonstrates these mechanisms of action. These are known quantities. Yeah.

And the great news is, is one can refer to the magnificent work of Dr. D'Agostino, which demonstrates these mechanisms of action. These are known quantities. Yeah.

Yeah, that's Dr. Slocum's group at the Chemothermia Clinic. In fact, he's published with Seyfried. So there's already a pre-existing collaboration there. Any number of the people that we've worked with have benefited from going to that clinic, which combines the standard of care with metabolic therapies.

Yeah, that's Dr. Slocum's group at the Chemothermia Clinic. In fact, he's published with Seyfried. So there's already a pre-existing collaboration there. Any number of the people that we've worked with have benefited from going to that clinic, which combines the standard of care with metabolic therapies.

Yeah, that's Dr. Slocum's group at the Chemothermia Clinic. In fact, he's published with Seyfried. So there's already a pre-existing collaboration there. Any number of the people that we've worked with have benefited from going to that clinic, which combines the standard of care with metabolic therapies.

Yeah, the feeling is always there's more work to do. In other words, it's always important to acknowledge what I like to call progress of a kind, but it's not over. And it's still not over. He's got work to do. We've got work to do. In other words, the task is not, and Dr. Howard put a fine point on this earlier, the task is not to make tumors disappear.

Yeah, the feeling is always there's more work to do. In other words, it's always important to acknowledge what I like to call progress of a kind, but it's not over. And it's still not over. He's got work to do. We've got work to do. In other words, the task is not, and Dr. Howard put a fine point on this earlier, the task is not to make tumors disappear.

Yeah, the feeling is always there's more work to do. In other words, it's always important to acknowledge what I like to call progress of a kind, but it's not over. And it's still not over. He's got work to do. We've got work to do. In other words, the task is not, and Dr. Howard put a fine point on this earlier, the task is not to make tumors disappear.

The standard of care is very effective that you can cut one out, you can burn one out, you can poison one out. That really doesn't contribute very much to overall survivorship. one must consistently and chronically impugn tumor viability in a sustainable fashion that makes the rest of the body healthy. That is the task.

The standard of care is very effective that you can cut one out, you can burn one out, you can poison one out. That really doesn't contribute very much to overall survivorship. one must consistently and chronically impugn tumor viability in a sustainable fashion that makes the rest of the body healthy. That is the task.

The standard of care is very effective that you can cut one out, you can burn one out, you can poison one out. That really doesn't contribute very much to overall survivorship. one must consistently and chronically impugn tumor viability in a sustainable fashion that makes the rest of the body healthy. That is the task.

So when we see improvement in people, yes, acknowledge and immediately back to work. You can never relent your vigilance in this regard. You have to keep your foot on the throttle. at all times. And that doesn't mean that you don't make adjustments, right? You do make adjustments.